SPY311.36-0.82 -0.26%
DIA263.33+0.16 0.06%
IXIC9,615.81-67.10 -0.69%
News
ASND
--
0.00%
--
Should You Avoid Ascendis Pharma A/S (ASND)?
Insider Monkey · 1d ago
Merit Medical Reaches Deal With Starboard Value
Barrons.com · 6d ago
Earnings Beat: Ascendis Pharma A/S (NASDAQ:ASND) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Simply Wall St. · 05/22 11:14
The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on May 20.)
Benzinga · 05/21 12:01
Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $181
Morgan Stanley maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $180 to $181.
Benzinga · 05/21 11:58
Stocks That Hit 52-Week Highs On Wednesday
During Wednesday's morning session, 85 stocks hit new 52-week highs.
Benzinga · 05/20 14:38
SVB Leerink Maintains Outperform on Ascendis Pharma, Raises Price Target to $173
SVB Leerink maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $170 to $173.
Benzinga · 05/20 13:50
Credit Suisse Maintains Outperform on Ascendis Pharma, Raises Price Target to $154
Credit Suisse analyst Tiago Fauth maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $149 to $154.
Benzinga · 05/20 12:24
Oppenheimer Maintains Outperform on Ascendis Pharma, Lowers Price Target to $208
Oppenheimer maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and lowers the price target from $219 to $208.
Benzinga · 05/20 12:23
Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/20 10:09
Ascendis Pharma Q1 EPS Euro (1.320) Beats Euro (1.500) Estimate
Ascendis Pharma (NASDAQ:ASND) reported quarterly losses of $(1.320) per share which beat the analyst consensus estimate of $(1.500) by 12 percent. This is a 4.35 percent increase over losses of $(1.380) per share from
Benzinga · 05/19 20:03
Ascendis Pharma A/S Reports First Quarter 2020 Financial Results
– On track for filing U.S. Biologics License Application for TransCon hGH in second quarter, and advancing Marketing Authorisation Application in Europe to third quarter  – –.
GlobeNewswire · 05/19 20:01
Ascendis Pharma A/S to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 19, 2020 / Ascendis Pharma A/S (NASDAQ:ASND) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 19, 2020 at 4:30 PM Eastern ...
ACCESSWIRE · 05/19 18:30
The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18)
Benzinga · 05/19 12:27
The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Earnings Flow Slows
Biotech stocks had another up week, with the American Society of Gene & Stem Cell Therapy virtual conference presentations and the ASCO abstracts made available online Thursday calling the shots. Earnings news flow continued to taper.
Benzinga · 05/17 16:30
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12)
Benzinga · 05/13 11:40
Stocks That Hit 52-Week Highs On Tuesday
Tuesday morning saw 85 companies set new 52-week highs.
Benzinga · 05/12 14:41
Ascendis Pharma A/S Will Appoint Jesper Høiland as Global Chief Commercial Officer
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will appoint Jesper Høiland as Global Chief Commercial Officer upon completion of his t
GlobeNewswire · 05/11 12:30
Ascendis Pharma A/S Announces First Quarter 2020 Financial Results and Business Update Conference Call on May 19
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will hold a conference call and live webcast on Tuesday, May 19, 2020 at 4:30 p.m. East
GlobeNewswire · 05/07 20:01
Biofrontera's New Deal, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 04/22 05:16